Liver cancer
Jul 14, 2026
Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab–Rivoceranib Combination in Advanced Liver Cancer Hengrui Pharma and Elevar Therapeutics have encountered another setback in their efforts to secure U.S. approval for the combination of camrelizumab and rivoceranib, as the FDA has issued a thir...
Read More...
Apr 07, 2026
Neurocrine Signs Deal to Acquire Soleno Therapeutics; AstraZeneca Shares Favorable Results from EMERALD-3 Study in Liver Cancer; Immunovant Presents Phase 3 Clinical Data for Batoclimab in TED; Alto Neuroscience Shares Topline Findings from Phase 2 ALTO-101 Study and Pipeline Updates; ORIC Positions Rinzimetostat for Phase 3 Success with Optimized Dosing Strategy
Neurocrine Announces Acquisition of Soleno Therapeutics to Broaden Rare Disease Portfolio Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics in a transaction valued at approximately $2.9 billion, marking a significant strategic expansion into the rare disease and metabo...
Read More...
Feb 06, 2024
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016
4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...
Read More...
Jan 24, 2023
BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy
FDA Approves BeiGene’s Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. SLL is...
Read More...
Aug 24, 2018
Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd
Hepato Cellular Carcinoma (HCC) Not all deadly battles are lost. Some are won too.It is without the slightest doubt that the ones won are the typical examples of smart management, involving implementation of prudent steps, guided by the knowledge of every nook and corner. Undoubtedly, these examples not only serve ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
